What is Retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a triple agonist at three key metabolic receptors — the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). This simultaneous triple receptor engagement gives Retatrutide research a uniquely complex mechanism of action that distinguishes it from earlier generation single and dual receptor agonists.
Retatrutide contains 39 amino acids and incorporates a fatty acid side chain that extends its half-life significantly compared to unmodified peptides. This structural modification is a key feature of its design and contributes to its pharmacokinetic profile.
The Three Receptor Targets
Understanding Retatrutide research requires understanding the three receptor systems it engages.
| Receptor | Primary Expression | Research Role |
|---|---|---|
| GLP-1 (GLP-1R) | Pancreas, brain, heart, GI tract | Glucose metabolism and appetite regulation — validated by first generation agonists including semaglutide |
| GIP (GIPR) | Adipose tissue, bone, brain, pancreas | Additive effects alongside GLP-1R agonism — basis for dual agonists including tirzepatide |
| Glucagon (GCGR) | Liver | Hepatic glucose production and energy expenditure — increases metabolic rate and fat oxidation |
Retatrutide in Clinical Research
Retatrutide has advanced further in clinical development than most research peptides, making it a particularly well documented compound in the scientific literature. Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 reported significant findings in participants with obesity, establishing Retatrutide as one of the most potent metabolic peptides studied to date.
The highest dose group in the Phase 2 trial demonstrated weight reductions that exceeded those reported for any previously studied metabolic peptide.
Phase 2 trial data, New England Journal of Medicine, 2023Phase 3 clinical trials are currently ongoing, examining Retatrutide across multiple indications including obesity, type 2 diabetes and metabolic dysfunction associated steatohepatitis (MASH).
Synthesis Complexity
At 39 amino acids Retatrutide is among the more complex peptides available for research purposes. Its synthesis via Solid Phase Peptide Synthesis requires 39 sequential coupling reactions, with each step carrying a small risk of incomplete reaction or side chain modification that can reduce overall purity.
The fatty acid side chain incorporation adds further synthetic complexity. Achieving purity levels of 99%+ for Retatrutide requires sophisticated preparative HPLC purification to remove truncated sequences and synthesis byproducts.
Storage and Stability
Retatrutide in its lyophilised form should be stored at 2-8°C for short term use and -20°C for long term storage. The fatty acid side chain modification improves stability compared to unmodified 39 amino acid peptides, but proper cold chain storage remains essential to maintaining research grade integrity.
| Property | Specification |
|---|---|
| Amino Acid Chain | 39 amino acids + fatty acid side chain |
| Molecular Weight | Approximately 4758 Da |
| Short Term Storage | 2–8°C |
| Long Term Storage | -20°C |
Reconstitution for Laboratory Use
Lyophilised Retatrutide reconstitutes in bacteriostatic water. Due to the fatty acid side chain the powder may take slightly longer to dissolve than simpler peptides. Gentle swirling rather than mechanical shaking is recommended during reconstitution to preserve peptide structure.
The resulting solution should be clear and colourless. Any cloudiness or precipitation may indicate degradation or reconstitution issues and the batch should be verified before use in research protocols.
Retatrutide Purity Verification
Given the synthesis complexity of Retatrutide, rigorous quality verification is particularly important. A comprehensive Certificate of Analysis should include HPLC purity data confirming minimum 99% purity, mass spectrometry data confirming the molecular weight at approximately 4758 Da, and batch specific documentation linking the certificate to the exact product supplied.
Our Retatrutide is independently verified by Janoshik Analytical before being cleared for sale, with a minimum specification of 99% purity. The QR code on every vial links directly to the live, publicly accessible certificate for that specific batch.
Retatrutide Legal Status in the UK
Retatrutide is not a licensed medicine in the United Kingdom. It is not approved by the MHRA for human or veterinary use. It is available for purchase and possession for genuine in vitro laboratory research purposes. Pureline Biolabs supplies Retatrutide exclusively under research use only conditions in compliance with UK regulations.